AbbVie Inc. vs Uber Technologies, Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Uber Technologies, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Uber Technologies, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Uber Technologies, Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $52.0B for Uber Technologies, Inc., while their respective market capitalizations stand at $451.5B and $177.2B. AbbVie Inc. is headquartered in United States and Uber Technologies, Inc. operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Uber Technologies, Inc.: Uber reported FY2025 revenue of $52.017 billion, net income attributable to Uber of $10.053 billion, and approximately 34,000 employees. Dara Khosrowshahi is CEO. The company operates Mobility, Delivery, Freight, advertising, subscriptions, and partner marketplace services.

AbbVie Inc. and Uber Technologies, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Uber Technologies, Inc..

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

Uber Technologies, Inc. business model: Uber makes money from mobility service fees, delivery marketplace fees, freight brokerage, advertising, Uber One subscriptions, financial partnerships, and platform services. The company does not own most of the vehicles, restaurants, or freight assets on the platform; it monetizes demand routing, pricing, payments, matching, merchant access, and marketplace data.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Uber Technologies, Inc..

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Uber Technologies, Inc. competitive advantage: Uber's advantage comes from local marketplace liquidity, brand recognition, routing data, payments, driver and courier networks, merchant relationships, subscriptions, and cross-sell between Mobility and Delivery.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Uber Technologies, Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Uber Technologies, Inc. growth strategy: Uber's growth strategy is focused on marketplace liquidity, cross-platform engagement, advertising, subscriptions, delivery scale, autonomous-vehicle partnerships, and disciplined unit economics. The pending Delivery Hero offer would extend delivery density and international market reach if it closes in the second half of 2027.

A closer look at the financial trajectory of AbbVie Inc. and Uber Technologies, Inc. rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

Uber Technologies, Inc.: Uber reported FY2025 revenue of $52.017 billion, up 18% from FY2024. Net income attributable to Uber was $10.053 billion, gross bookings were $193.454 billion, trips were 13.567 billion, and MAPCs reached 202 million. The company had approximately 34,000 employees at year-end 2025.